NCT04166565 2026-04-20
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT07107529 2026-04-15
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Recruiting
NCT05289687 2026-04-03
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT03896737 2025-08-11
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT06189833 2024-04-23
TAURUS
European Myeloma Network B.V.
Phase 2 Recruiting